5-羟基-1-甲基-3,4-二氢喹啉-2-酮 | 34591-83-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5-羟基-1-甲基-3,4-二氢喹啉-2-酮
• 英文名称: 5-hydroxy-1-methyl-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 5-hydroxy-N-methyl-3,4-dihydroquinolin-2(1H)-one；1-methyl-5-hydroxy-3,4-dihydrocarbostyril；5-hydroxy-1-methyl-3,4-dihydro-2-quinolone；5-Hydroxy-1-methyl-3,4-dihydroquinolin-2-one
• CAS: 34591-83-8
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: PXWAZDGOXQPIGF-UHFFFAOYSA-N

物化性质

• 沸点：
  438.7±45.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-羟基-1-甲基-3,4-二氢喹啉-2-酮 在 N-溴代丁二酰亚胺(NBS) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 sodium acetate 、 二异丙胺 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 生成 methyl 5-hydroxy-1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-carboxylate
  参考文献：
  名称：

  [EN] QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] COMPOSÉS QUINAZOLINE UTILES EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1

  摘要：

  本发明涉及以下式的化合物（式（I））及其药学上可接受的盐，其中X、Y、Z、R1、R7、R8、R9、R11、n和p在此处定义。式（I）的化合物是M1受体阳性变构调节剂，对治疗M1受体参与的疾病，包括阿尔茨海默病、精神分裂症、疼痛和睡眠障碍等方面具有用处。该发明还涉及包含式（I）化合物和药学上可接受载体的药物组合物，以及使用式（I）化合物治疗由M1受体介导的疾病的方法。

  公开号：

  WO2017155816A1
• 作为产物：
  描述：

  5-bromo-1-methyl-3,4-dihydroquinolin-2(1H)-one 在 2-二叔丁基膦-3,4,5,6-四甲基-2′,4′,6′-三异丙基-1,1′-联苯 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成 5-羟基-1-甲基-3,4-二氢喹啉-2-酮
  参考文献：
  名称：

  [EN] QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] COMPOSÉS QUINAZOLINE UTILES EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1

  摘要：

  本发明涉及以下式的化合物（式（I））及其药学上可接受的盐，其中X、Y、Z、R1、R7、R8、R9、R11、n和p在此处定义。式（I）的化合物是M1受体阳性变构调节剂，对治疗M1受体参与的疾病，包括阿尔茨海默病、精神分裂症、疼痛和睡眠障碍等方面具有用处。该发明还涉及包含式（I）化合物和药学上可接受载体的药物组合物，以及使用式（I）化合物治疗由M1受体介导的疾病的方法。

  公开号：

  WO2017155816A1

文献信息

• Pharmaceutically useful carbostyril derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04734416A1

  公开（公告）日：1988-03-29

  Carbostyril derivatives having antihistamic action and central nervous controlling action are useful as antihistamic agents or central nervous controlling agents. The derivatives are represented by the general formula, ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms or a phenylalkyl group having an alkylene group containing 1 to 4 carbon atoms; R.sup.2 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a phenyl group; R.sup.3 is a hydrogen atom, a hydroxy group, an alkyl group having 1 to 4 carbon atoms, an alkanolyoxy group having 1 to 4 carbon atoms or a 3,4,5-trimethoxybenzoyloxy group; R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R.sup.5 is a cycloalkyl group having 3 to 8 carbon atoms, a phenyl group (which may have 1 to 3 substituted groups selected from the group consisting of halogen atoms, alkyl groups having 1 to 4 carbon atoms and alkoxy groups having 1 to 4 carbon atoms), an alkyl group having 1 to 4 carbon atoms (having one substituted group such as a hydroxy group, a phenyl group or an alkanoyloxy group having 1 to 4 carbon atoms), an alkanoyl group having 1 to 4 carbon atoms or benzoyl group; X is a halogen atom; n is 0, or an integer of 1 or 2; Q is an integer of 2 or 3, l and m are respectively an integer of 0 or 1-6, but the sum of l and m should not exceed 6; the carbon-carbon bond at the 3- and 4-positions in the carbostyril skeleton is a single or double bond; and the substituted position of the side chain of ##STR2## is any one of the 4-, 5-, 6-, 7- or 8-positions.

  卡波司酯衍生物具有抗组胺作用和中枢神经控制作用，可用作抗组胺剂或中枢神经控制剂。这些衍生物由通式所代表，其中R.sup.1是氢原子、具有1至6个碳原子的烷基基团、具有2至4个碳原子的烯基基团、具有2至4个碳原子的炔基基团或含有1至4个碳原子的烷基基团的苯基基团；R.sup.2是氢原子、具有1至4个碳原子的烷基基团或苯基团；R.sup.3是氢原子、羟基、具有1至4个碳原子的烷基基团、具有1至4个碳原子的烷酰氧基团或3,4,5-三甲氧基苯甲酰氧基团；R.sup.4是氢原子或具有1至4个碳原子的烷基基团；R.sup.5是具有3至8个碳原子的环烷基基团、苯基（可能有1至3个卤素原子、具有1至4个碳原子的烷基基团和具有1至4个碳原子的烷氧基团中选择的取代基）、具有1至4个碳原子的烷基基团（具有一个取代基，如羟基、苯基或具有1至4个碳原子的烷酰氧基团）、具有1至4个碳原子的烷酰基或苯甲酰基；X是卤素原子；n为0或1或2的整数；Q为2或3的整数，l和m分别为0或1至6的整数，但l和m的总和不应超过6；卡波司酯骨架中3-位和4-位的碳-碳键为单键或双键；以及##STR2##的侧链的取代位置为4-、5-、6-、7-或8-位中的任意一个。
• An Efficient p-Thiocyanation of Phenols and Naphthols Using a Reagent Combination of Phenyliodine Dichloride and Lead(II) Thiocyanate.
  作者：Yasuyuki KITA、Yoshifumi TAKEDA、Takayuki OKUNO、Masahiro EGI、Kiyosei IIO、Ken-ichi KAWAGUCHI、Shuji AKAI

  DOI：10.1248/cpb.45.1887

  日期：——

  A combination of PhICl2 and Pb(SCN)2 is effective for the p-selective thiocyanation of various types of p-unsubstituted phenols and naphthols 1 to give p-thiocyanatophenols and naphthols 3. The reaction proceeded at 0°C to room temperature in good to quantitative yields. Twenty-five examples are given, in which various functional groups, such as chloro, allyl, carbonyl, ester, amide, and primary hydroxyl groups, are shown to be compatible with this reaction.

  PhICl2 和 Pb(SCN)2 的组合可有效地对各种类型的对未取代苯酚和萘酚 1 进行对选择性硫氰酸化，从而得到对硫氰酸苯酚和萘酚 3。反应在 0°C 至室温下进行，产率高至定量。文中给出了 25 个例子，表明氯基、烯丙基、羰基、酯基、酰胺基和伯羟基等各种官能团与该反应相容。
• Glycerol derivatives of quinoline carbostyryl and isocarbo styryl
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04065456A1

  公开（公告）日：1977-12-27

  A glycerol derivative represented by the formula (I) ##STR1## wherein A is hereinafter defined, including the optically active isomers per se and mixtures of the optically active isomers, which are useful as a central nervous system depressant, an intermediate for the preparation of .beta.-adrenergic blocking agents, an inhibitor of blood platelet aggregation or a choleretic agent, and a process for preparing the above glycerol derivative.

  一种由公式(I)表示的甘油衍生物：##STR1## 其中A在此后被定义，包括本身的光学活性异构体和光学活性异构体的混合物，其可用作中枢神经系统抑制剂、制备β-肾上腺素能阻滞剂的中间体、血小板聚集抑制剂或胆汁排泄剂，以及制备上述甘油衍生物的方法。
• Carbostyril derivatives and pharmaceutical preparations containing same
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04824840A1

  公开（公告）日：1989-04-25

  Carbostyril derivatives having antihistaminic action and central nervous controlling action are useful as antihistaminic agents or central nervous controlling agents. The derivatives are represented by the general formula, ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms or a phenylalkyl group, an alkylene group containing 1 to 4 carbon atoms; R.sup.2 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a phenyl group; R.sup.3 is a hydrogen atom, a hydroxy group, an alkyl group having 1 to 4 carbon atoms, an alkanoyloxy group having 1 to 4 carbon atoms or a 3,4,5-trimethoxybenzoyloxy group; R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R.sup.5 is a cycloalkyl group having 3 to 8 carbon atoms, a phenyl group (which may have 1 to 3 substituted groups selected from the group consisting of halogen atoms, alkyl groups having 1 to 4 carbon atoms and alkoxy groups having 1 to 4 carbon atoms), an alkyl group having 1 to 4 carbon atoms (having one substituted group such as a hydroxy group, a phenyl group or an alkanoyloxy group having 1 to 4 carbon atoms), an alkanoyl group having 1 to 4 carbon atoms or benzoyl group; X is a halogen atom; n is 0, or an integer of 1 or 2; Q is an integer of 2 or 3, l and m are respectively an integer of 0 to 1-6, but the sum of l and m should not exceed 6; the carbon-carbon bond at the 3- and 4-positions in the carbostyril skeleton is a single or double bond and; the substituted position of the side chain of ##STR2## is any one of the 4-, 5-, 6-, 7- or 8-positions.

  羧基苯基吡啶衍生物具有抗组胺作用和中枢神经控制作用，可用作抗组胺剂或中枢神经控制剂。该衍生物由通式## STR1 ##表示，其中R.sup.1是氢原子，具有1至6个碳原子的烷基，具有2至4个碳原子的烯基，具有2至4个碳原子的炔基或苯基烷基，含有1至4个碳原子的烷基，R.sup.2是氢原子，具有1至4个碳原子的烷基或苯基，R.sup.3是氢原子，羟基，具有1至4个碳原子的烷基，具有1至4个碳原子的烷酰氧基或3,4,5-三甲氧基苯甲酰氧基，R.sup.4是氢原子或具有1至4个碳原子的烷基，R.sup.5是具有3至8个碳原子的环烷基，苯基（可能具有1至3个取代基，所述取代基选自卤原子，具有1至4个碳原子的烷基和具有1至4个碳原子的烷氧基），具有1至4个碳原子的烷基（具有一个取代基，例如羟基，苯基或具有1至4个碳原子的烷酰氧基），具有1至4个碳原子的烷酰基或苯甲酰基; X是卤原子; n为0或1或2的整数; Q为2或3的整数，l和m分别为0至1-6的整数，但l和m的总和不应超过6;羧基吡啶骨架中3-和4-位置的碳-碳键是单键或双键; ## STR2 ##的侧链的取代位置是4-，5-，6-，7-或8-位置之一。
• Carbostyril derivatives
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0467325A2

  公开（公告）日：1992-01-22

  Carbostyril derivatives of Formula I: wherein: m is 0, 1, or 2; n is 0, 1, or 2; R1 is hydrogen or lower alkyl; R2 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, aralkoxy, or acyloxy; R3 is hydrogen, halogen, lower alkyl, or lower alkoxy; R4 is hydrogen, hydroxy, lower alkyl, or acyloxy, provided that when R4 is hydroxy or acyloxy, m and n are both 1; R5 is hydrogen or lower alkyl; and R6 is alkyl, hydroxyalkyl, alkoxyalkyl, or (dialkylamino)alkyl; and the pharmaceutically acceptable acid addition salts and N-oxides (at the carbostyril nitrogen) thereof, and compositions containing them, are useful in treating cardiovascular diseases, particularly arrhythmias. Methods of preparing intermediates, the compounds, and their formulations are also disclosed.

  式 I 的喹诺酮衍生物： 其中 m 是 0、1 或 2 n 是 0、1 或 2 R1 是氢或低级烷基 R2 是氢、卤素、羟基、低级烷基、低级烷氧基、芳基氧基或酰氧基； R3 是氢、卤素、低级烷基或低级烷氧基； R4 是氢、羟基、低级烷基或酰氧基、 但当 R4 为羟基或酰氧基时，m 和 n 均为 1； R5 是氢或低级烷基；R6 是烷基、羟基烷基、烷氧基烷基或（二烷基氨基）烷基； 及其药学上可接受的酸加成盐和 N-氧化物（碳氮基），以及含有它们的组合物，可用于治疗心血管疾病，特别是心律失常。还公开了制备中间体、化合物及其制剂的方法。